State of the art in breast intraoperative electron radiation therapy after intraoperative ultrasound introduction
, , , , , , , , , y | 16 may 2021
Acerca de este artículo
Article Category: Research Article
Publicado en línea: 16 may 2021
Páginas: 333 - 340
Recibido: 12 nov 2020
Aceptado: 06 abr 2021
DOI: https://doi.org/10.2478/raon-2021-0023
© 2021 Cristiana Vidali, Mara Severgnini, Gabriele Bellio, Fabiola Giudici, Vittorino Milan, Zaira Pellin, Sara Savatovic, Serena Scomersi, Gerd Fastner, Antonella Ciabattoni, Marina Bortul, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Figure 2A
Figure 2B
Figure 3
Acute toxicity of radiotherapy in the two groups
| Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
|---|---|---|---|
| 23 (60.5%) | 36 (50%) | 59 (53.6%) | |
| 8 (21.1%) | 28 (38.9%) | 36 (32.7%) | |
| 6 (15.8%) | 7 (9.7%) | 13 (11.8%) | |
| 1 (2.6%) | 1 (1.4%) | 2 (1.9%) | |
| 14 (36.8%) | 35 (48.6%) | 49 (44.5%) |
Late toxicity of radiotherapy in the two groups
| Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
|---|---|---|---|
| 22 (57.9%) | 43 (59.7%) | 65 (59.1%) | |
| 12 (31.6%) | 24 (33.3%) | 36 (32.7%) | |
| 3 (7.9%) | 3 (4.2%) | 6 (5.5%) | |
| 1 (2.6%) | 2 (2.8%) | 3 (2.7%) | |
| 15 (39.5%) | 27 (37.5%) | 42(38.2%) |
Description of the population
| Variables | All cohort (n = 110) | Group 1 (n = 38) | Group 2 (n = 72) | p-value |
|---|---|---|---|---|
| Age (years) Median (range) | 67 (43−85) | 67 (48−80) | 67 (43−85) | p = 0.51 |
| Clinical stage | ||||
| cT1a N0 | 2 (1.8%) | 1 (2.6%) | 1 (1.4%) | |
| cT1b N0 | 47 (42.8%) | 20 (52.6%) | 27 (37.5%) | |
| cT1c N0 | 59 (53.6%) | 17 (44.8%) | 42 (58.3%) | p = 0.42 |
| cT1b N1 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| cT2 N0 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| Histological type | ||||
| Ductal carcinoma in situ (DCIS) | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
| Invasive ductal carcinoma | 70 (63.6%) | 26 (68.4%) | 44 (61.1%) | p = 0.46 |
| Invasive lobular carcinoma | 19 (17.3%) | 5 (13.2%) | 14 (19.45%) | |
| Others | 20 (18.2%) | 6 (15.8%) | 14 (19.45%) | |
| Multifocal disease | 6 (5.4%) | 4 (10.5%) | 2 (2.8%) | p = 0.21 |
| Pathological Stage pT | ||||
| pTis | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
| pT1a | 3 (2.7%) | 0 (0.0%) | 3 (4.2%) | |
| pT1b | 41 (37.3%) | 16 (42.1%) | 25 (34.7%) | p=0.40 |
| pT1c | 59 (53.6%) | 20 (52.6%) | 39 (54.2%) | |
| pT2 | 6 (5.5%) | 1 (2.6%) | 5 (6.9%) | |
| Pathological Stage pN | ||||
| pN0 | 88 (80.0%) | 32 (84.2%) | 56 (77.8%) | |
| pN1mi | 7 (6.4%) | 3 (7.9%) | 4 (5.6%) | p=0.71 |
| pN1a | 14 (12.7%) | 3 (7.9%) | 11 (15.3%) | |
| pN3 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| Grading | ||||
| G1 | 15 (13.7%) | 7(18.4%) | 8 (11.1%) | |
| G2 | 68 (61.8%) | 24 (63.2%) | 44 (61.1%) | p = 0.67 |
| G3 | 21 (19.1%) | 6 (15.8%) | 15 (20.8%) | |
| Gx | 6 (5.4%) | 1 (2.6%) | 5 (7%) | |
| Adjuvant therapy Calculated on 109 patients |
||||
| None | 2 (1.8%) | 0 (0.0%) | 2 (2.8%) | |
| Chemotherapy | 6 (5.5%) | 2 (5.4%) | 4 (5.6%) | p = 0.92 |
| Endocrine therapy | 85 (78%) | 29 (78.4%) | 56 (77.7%) | |
| Chemotherapy + Endocrine therapy | 12 (11%) | 4 (10.8%) | 8 (11.1%) | |
| Chemotherapy + Trastuzumab | 4 (3.7%) | 2 (5.4%) | 2 (2.8%) |